Hays E F, Weinroth S E, MacLeod C L, Kitada S
Int J Cancer. 1986 Oct 15;38(4):597-601. doi: 10.1002/ijc.2910380421.
Stable hybrids formed between clones of established murine T-cell lymphoma lines, and between lymphoma clones and normal spleen or thymus cells were examined for their tumorigenic properties by intravenous (i.v.) and intradermal (i.d.) inoculation into syngeneic AKR mice. Fusion parents consisted of T lymphoma clones of high and low tumorigenicity derived from the SL 12 cell line. In addition, normal spleen cells and thymocytes were fused with poorly tumorigenic T-lymphoma clones. Hybrids tested by i.v. inoculation of 10(6) cells to syngeneic hosts showed that fusion between the lymphoma cells resulted in hybrids which displayed the phenotype of the highly tumorigenic parent. Also, it was shown that fusion of poorly tumorigenic lymphoma cells with normal spleen cells resulted in hybrids with enhanced tumorigenicity. Fusion of poorly tumorigenic lymphoma cells with normal thymocytes resulted in hybrids with the highest tumorigenic potential. The pattern of spread for the tumor/tumor hybrid was that of the highly tumorigenic parent. Tumor spread patterns for the spleen/tumor hybrids were different from those of the thymocyte/tumor hybrids. Intradermal inoculation of 10(5) cells from tumor/spleen or tumor/thymocyte hybrids revealed differences in latent periods between parental and hybrid cells, the tumor/thymocyte hybrids having the shortest latent period. Surface marker studies and T-cell antigen receptor mRNA determinations in the tumor cell/normal cell hybrids indicated that the normal parent was a cell of immature phenotype. Therefore, high tumorigenicity is a dominant characteristic, and poorly tumorigenic but "immortal" T lymphoma cells can derive characteristics which increase their in vivo growth capacity from the putative immature normal cells with which they selectively fuse.
通过将已建立的小鼠T细胞淋巴瘤系的克隆之间，以及淋巴瘤克隆与正常脾细胞或胸腺细胞之间形成的稳定杂交体，经静脉（i.v.）和皮内（i.d.）接种到同基因AKR小鼠中，检测它们的致瘤特性。融合亲本包括源自SL 12细胞系的高致瘤性和低致瘤性的T淋巴瘤克隆。此外，正常脾细胞和胸腺细胞与低致瘤性T淋巴瘤克隆进行融合。通过向同基因宿主静脉接种10⁶个细胞对杂交体进行检测，结果显示淋巴瘤细胞之间的融合产生的杂交体表现出高致瘤性亲本的表型。而且，还表明低致瘤性淋巴瘤细胞与正常脾细胞融合产生的杂交体致瘤性增强。低致瘤性淋巴瘤细胞与正常胸腺细胞融合产生的杂交体具有最高的致瘤潜力。肿瘤/肿瘤杂交体的扩散模式与高致瘤性亲本相同。脾/肿瘤杂交体的肿瘤扩散模式与胸腺细胞/肿瘤杂交体不同。对肿瘤/脾或肿瘤/胸腺细胞杂交体的10⁵个细胞进行皮内接种，结果显示亲本细胞与杂交体细胞在潜伏期上存在差异，肿瘤/胸腺细胞杂交体的潜伏期最短。对肿瘤细胞/正常细胞杂交体进行表面标志物研究和T细胞抗原受体mRNA测定表明，正常亲本是未成熟表型的细胞。因此，高致瘤性是一个显性特征，低致瘤性但“永生”的T淋巴瘤细胞可以从与其选择性融合的假定未成熟正常细胞中获得增强其体内生长能力的特征。
